[go: up one dir, main page]

PT1660491E - Derivados de benzimidazole, benzotiazole e benzoxazole e a sua utilização como moduladores de lta4h - Google Patents

Derivados de benzimidazole, benzotiazole e benzoxazole e a sua utilização como moduladores de lta4h Download PDF

Info

Publication number
PT1660491E
PT1660491E PT04779219T PT04779219T PT1660491E PT 1660491 E PT1660491 E PT 1660491E PT 04779219 T PT04779219 T PT 04779219T PT 04779219 T PT04779219 T PT 04779219T PT 1660491 E PT1660491 E PT 1660491E
Authority
PT
Portugal
Prior art keywords
benzthiazole
benzimidazole
benzoxazole derivatives
lta4h modulators
lta4h
Prior art date
Application number
PT04779219T
Other languages
English (en)
Inventor
James P Edwards
Cheryl A Grice
Jianmei Wei
Frank U Axe
Scott D Bembenek
Christopher R Butler
Anne M Fourie
Brad M Savall
Kevin L Tays
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT1660491E publication Critical patent/PT1660491E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ceramic Engineering (AREA)
  • Pulmonology (AREA)
  • Manufacturing & Machinery (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT04779219T 2003-07-28 2004-07-27 Derivados de benzimidazole, benzotiazole e benzoxazole e a sua utilização como moduladores de lta4h PT1660491E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49071003P 2003-07-28 2003-07-28

Publications (1)

Publication Number Publication Date
PT1660491E true PT1660491E (pt) 2008-10-10

Family

ID=34115427

Family Applications (2)

Application Number Title Priority Date Filing Date
PT04779219T PT1660491E (pt) 2003-07-28 2004-07-27 Derivados de benzimidazole, benzotiazole e benzoxazole e a sua utilização como moduladores de lta4h
PT04779375T PT1660492E (pt) 2003-07-28 2004-07-27 Derivados de benzimidazole, benzotiazole e benzoxazole e sua utilização como moduladores de lta4h

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT04779375T PT1660492E (pt) 2003-07-28 2004-07-27 Derivados de benzimidazole, benzotiazole e benzoxazole e sua utilização como moduladores de lta4h

Country Status (28)

Country Link
US (2) US20050043379A1 (pt)
EP (2) EP1660491B1 (pt)
JP (2) JP2007500703A (pt)
KR (2) KR20060054408A (pt)
CN (2) CN1856490A (pt)
AR (2) AR045729A1 (pt)
AT (2) ATE403654T1 (pt)
AU (2) AU2004261628B2 (pt)
BR (2) BRPI0412345A (pt)
CA (2) CA2534212A1 (pt)
CY (1) CY1108560T1 (pt)
DE (2) DE602004016002D1 (pt)
DK (2) DK1660491T3 (pt)
ES (2) ES2311858T3 (pt)
HR (2) HRP20060041B1 (pt)
IL (1) IL173372A (pt)
MY (1) MY145080A (pt)
NO (2) NO20060771L (pt)
NZ (2) NZ544970A (pt)
PL (2) PL1660492T3 (pt)
PT (2) PT1660491E (pt)
RU (2) RU2359970C2 (pt)
SG (2) SG130192A1 (pt)
SI (2) SI1660491T1 (pt)
TW (2) TW200520756A (pt)
UA (2) UA87986C2 (pt)
WO (2) WO2005012297A1 (pt)
ZA (2) ZA200601716B (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1856490A (zh) * 2003-07-28 2006-11-01 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
CN101189012A (zh) * 2005-03-31 2008-05-28 詹森药业有限公司 苯基和吡啶基lta4h调节剂
WO2006109075A2 (en) 2005-04-13 2006-10-19 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of hsp90
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
BRPI0615449A2 (pt) * 2005-09-02 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método de tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de sst do subtipo 5 e uso desses compostos
AU2006297798B2 (en) * 2005-09-21 2013-01-31 Decode Genetics Ehf. Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation
WO2007073407A1 (en) * 2005-12-21 2007-06-28 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
US7674802B2 (en) 2005-12-21 2010-03-09 Decode Genetics, Ehf N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation
AU2006333522A1 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation
LT1976828T (lt) 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
US8354434B2 (en) * 2006-01-30 2013-01-15 Purdue Pharma L.P. Cyclourea compounds as calcium channel blockers
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
WO2008019302A1 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Pyrazolylphenyl and pyrrolylphenyl inhibitors of lta4h for treating inflammation
WO2008019306A2 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
WO2008019284A1 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of lta4h for treating inflammation
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
EP2073804B1 (en) 2006-10-12 2017-09-13 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in the treatment of pain
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
JP2010520878A (ja) * 2007-03-08 2010-06-17 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性の調節剤としての化合物および組成物
WO2008120710A1 (ja) * 2007-03-30 2008-10-09 Panasonic Electric Works Co., Ltd. 活動強度計
AR069126A1 (es) * 2007-10-31 2009-12-30 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
NZ601350A (en) * 2007-11-16 2013-08-30 Abbvie Inc Method of treating arthritis
SI2336125T1 (sl) * 2008-04-11 2013-04-30 Janssen Pharmaceutica N.V. Tiazolopiridin-2-iloksi-fenil in tiazolopirazin-2-iloksi-fenil amini kot modulatorji levkotrien a4 hidrolaze
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
CN105622580B (zh) 2008-04-28 2019-06-21 詹森药业有限公司 作为脯氨酰羟化酶抑制剂的苯并咪唑
CN102459251B (zh) * 2009-05-14 2015-05-20 詹森药业有限公司 作为白三烯a4水解酶的调节剂的具有两个稠合双环杂芳基部分的化合物
CN102442961A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-甲基四氮唑的生产方法
CN102442962A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-烷基四氮唑的生产方法
EP3461820B1 (en) 2011-10-25 2020-07-29 Janssen Pharmaceutica NV Method for obtaining crystals of meglumine salt of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
JP6527851B2 (ja) 2013-03-12 2019-06-05 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素を阻害する方法
BR112015022226A2 (pt) 2013-03-14 2017-07-18 Celtaxsys Inc inibidores de leucotrieno a4 hidrolase
MX2015011678A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
AU2014239585B2 (en) 2013-03-14 2019-04-04 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
JP6212644B2 (ja) * 2013-12-17 2017-10-11 イーライ リリー アンド カンパニー フェノキシエチル環状アミン誘導体およびｅｐ４受容体モジュレーターとしてのその活性
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
JP6549735B2 (ja) 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド 核内受容体調節剤
KR102390246B1 (ko) 2016-12-21 2022-04-22 에프. 호프만-라 로슈 아게 항체의 시험관내 글리코조작에 있어서의 효소의 재사용
AU2017381657B2 (en) 2016-12-21 2020-07-23 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of antibodies
CN107663192B (zh) * 2017-11-03 2019-05-10 梯尔希（南京）药物研发有限公司 一种雷贝拉唑杂质的制备方法
US10898484B2 (en) 2018-05-31 2021-01-26 Celltaxis, Llc Method of reducing pulmonary exacerbations in respiratory disease patients
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP7680955B2 (ja) * 2019-01-11 2025-05-21 ネイジス ファーマシューティカルズ インコーポレイテッド ロイコトリエン合成阻害剤
CN110026557B (zh) * 2019-05-28 2021-08-27 南方科技大学 一种混合固体颗粒重熔的直写装置及成型方法
WO2022109209A1 (en) * 2020-11-19 2022-05-27 Telo Therapeutics, Inc. Small molecule compounds and compositions
US11932630B2 (en) * 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN113683491A (zh) * 2021-09-01 2021-11-23 王传良 一种4-(2-溴乙基)苯酚的制备方法
CN113735798B (zh) * 2021-09-27 2022-07-12 安徽美致诚药业有限公司 一种盐酸罗沙替丁醋酸酯的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
DK171349B1 (da) * 1986-11-14 1996-09-16 Hoffmann La Roche Tetrahydronaphthalenderivater, fremgangsmåde til fremstilling deraf, lægemidler indeholdende forbindelserne samt anvendelse af forbindelserne til fremstilling af lægemidler
IL90337A0 (en) * 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
IT1240598B (it) * 1990-03-13 1993-12-17 Mini Ricerca Scient Tecnolog Derivati amminici ad azione antifungina
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
AU3297099A (en) * 1998-02-25 1999-09-15 Genetics Institute Inc. Inhibitors of phospholipase a2
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20040110757A1 (en) * 2002-03-21 2004-06-10 Thomas Arrhenius Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
CN1856490A (zh) * 2003-07-28 2006-11-01 詹森药业有限公司 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
AU2006224842B2 (en) * 2005-03-16 2011-09-29 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof

Also Published As

Publication number Publication date
EP1660492B1 (en) 2008-08-20
DE602004016002D1 (de) 2008-10-02
TW200523255A (en) 2005-07-16
TWI362383B (en) 2012-04-21
AU2004261628A1 (en) 2005-02-10
HRP20060041A2 (en) 2006-11-30
NZ544938A (en) 2009-05-31
NZ544970A (en) 2009-02-28
ATE403654T1 (de) 2008-08-15
HRP20060041B1 (hr) 2014-06-06
US20050043379A1 (en) 2005-02-24
WO2005012296A1 (en) 2005-02-10
AU2004261628B2 (en) 2011-05-12
CA2534228A1 (en) 2005-02-10
HRP20060039A2 (en) 2006-08-31
CN1856490A (zh) 2006-11-01
PL1660492T3 (pl) 2009-01-30
TW200520756A (en) 2005-07-01
DE602004015620D1 (de) 2008-09-18
RU2006102510A (ru) 2006-07-27
US20050043378A1 (en) 2005-02-24
ATE405562T1 (de) 2008-09-15
SI1660491T1 (sl) 2009-02-28
PL1660491T3 (pl) 2009-01-30
PT1660492E (pt) 2008-11-13
ES2313079T3 (es) 2009-03-01
IL173372A0 (en) 2006-06-11
MY145080A (en) 2011-12-15
DK1660492T3 (da) 2008-11-03
KR20060054408A (ko) 2006-05-22
EP1660491A1 (en) 2006-05-31
EP1660491B1 (en) 2008-08-06
WO2005012297A9 (en) 2007-01-04
HK1092790A1 (en) 2007-02-16
BRPI0413072A (pt) 2006-10-03
AU2004261610A1 (en) 2005-02-10
NO20060771L (no) 2006-04-21
ZA200601716B (en) 2007-05-30
KR101149379B1 (ko) 2012-06-28
UA87986C2 (uk) 2009-09-10
RU2359970C2 (ru) 2009-06-27
BRPI0412345A (pt) 2006-10-03
AR045729A1 (es) 2005-11-09
CA2534212A1 (en) 2005-02-10
DK1660491T3 (da) 2008-11-10
NO20060823L (no) 2006-03-15
JP2007500706A (ja) 2007-01-18
KR20060057593A (ko) 2006-05-26
CN1860117A (zh) 2006-11-08
RU2373204C2 (ru) 2009-11-20
HK1090359A1 (en) 2006-12-22
ES2311858T3 (es) 2009-02-16
SG130192A1 (en) 2007-03-20
UA82888C2 (en) 2008-05-26
IL173372A (en) 2010-11-30
WO2005012297A1 (en) 2005-02-10
SG129449A1 (en) 2007-02-26
CN100591679C (zh) 2010-02-24
AR045730A1 (es) 2005-11-09
CY1108560T1 (el) 2014-04-09
EP1660492A1 (en) 2006-05-31
AU2004261610B2 (en) 2010-05-20
JP2007500703A (ja) 2007-01-18
RU2006102508A (ru) 2006-07-27
ZA200601720B (en) 2007-11-28
JP4726238B2 (ja) 2011-07-20
SI1660492T1 (sl) 2009-02-28

Similar Documents

Publication Publication Date Title
SG129449A1 (en) Benzimidazole, benzthiazole and benzoxazole derivatives and their use as LTA4H modulators
IL232313A0 (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the aforementioned
PL375764A1 (en) Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
PL374693A1 (en) Novel benzimidazole derivatives
DE60335031D1 (de) Befestigter anordnungskörper, verbinder und hydraulikzylindereinheit
DE602004031733D1 (de) Medizinischer leitungsadapter
PT1626964E (pt) Novos derivados de benzimidazole
AU2003300131A8 (en) Indole derivatives as ppar modulators
IL172894A0 (en) Indol-6-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
HRP20041030A2 (en) Benzoxazine derivatives as 5-ht6 modulators and uses thereof
IL172891A0 (en) Indol-5-yl-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
AU2003278814A8 (en) Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof
PL1912644T3 (pl) Pochodne n-(aryloalkilo)-1H-pirolopirydyno-2-karboksyamidów, ich wytwarzanie i ich zastosowanie do leczenia
IL178259A0 (en) Novel benzothiazoles and the use thereof as medicaments
SI1532141T1 (sl) 2-pirolidin-2-il-(1,3,4)-oksadiazolni derivati in njihova uporaba kot antidepresivi
TWI348382B (en) N-acetylglucosamine derivatives, and the use thereof
AU2003285498A1 (en) Benzoxazole, benzthiazole and benzimidazole derivatives useful as heparanase inhibitors
IL175137A0 (en) Bace455, an alternative splice variant of the human beta-secretase
IL172750A0 (en) Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
IS8446A (is) Staðgengin bensimidasól-, benstríasól- og bensimidasólon-o-glúkósíð
EE04957B1 (et) Kompositsioon ja selle kasutamine raviva, profülaktilise ja kosmeetilise vahendina
DOP2002000500A (es) Benzamida, heteroarilamida y amidas inversas
SI1506179T1 (sl) Derivati benzoksazina kot modulatorji 5-ht6 in njihova uporaba